D Solomon

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial
    D Solomon
    Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Natl Cancer Inst 93:293-9. 2001
  2. ncbi request reprint The 2001 Bethesda System: terminology for reporting results of cervical cytology
    Diane Solomon
    EPN Room 2130, 6130 Executive Blvd, Bethesda, MD 20892, USA
    JAMA 287:2114-9. 2002
  3. ncbi request reprint ASCUS LSIL Triage Study (ALTS) conclusions reaffirmed: response to a November 2001 commentary
    Diane Solomon
    Division of Cancer Prevention, National Cancer Institute, Maryland, USA
    Obstet Gynecol 99:671-4. 2002
  4. ncbi request reprint Update on cervical screening
    Diane Solomon
    National Cancer Institute, Division of Cancer Prevention, National Institute of Health, 6130 Executive Blvd, EPN 2130, Rockville, MD 20852, USA
    Gynecol Oncol 99:S13. 2005
  5. ncbi request reprint Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study
    M E Sherman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 7080, Rockville, MD 20852-7374, USA
    Am J Clin Pathol 116:386-94. 2001
  6. pmc Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 203:814-22. 2011
  7. ncbi request reprint Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities
    Diane Solomon
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Obstet Gynecol 110:288-95. 2007
  8. ncbi request reprint 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ
    Thomas C Wright
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY, USA
    J Low Genit Tract Dis 11:223-39. 2007
  9. ncbi request reprint 2006 consensus guidelines for the management of women with abnormal cervical screening tests
    Thomas C Wright
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY, USA
    J Low Genit Tract Dis 11:201-22. 2007
  10. pmc Risk assessment to guide the prevention of cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    Am J Obstet Gynecol 197:356.e1-6. 2007

Collaborators

Detail Information

Publications57

  1. ncbi request reprint Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial
    D Solomon
    Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Natl Cancer Inst 93:293-9. 2001
    ..Effective colposcopy triage strategies are needed to identify the minority of women who have clinically significant disease while avoiding excessive follow-up evaluation for others...
  2. ncbi request reprint The 2001 Bethesda System: terminology for reporting results of cervical cytology
    Diane Solomon
    EPN Room 2130, 6130 Executive Blvd, Bethesda, MD 20892, USA
    JAMA 287:2114-9. 2002
    ..A primary objective was to develop a new approach to broaden participation in the consensus process...
  3. ncbi request reprint ASCUS LSIL Triage Study (ALTS) conclusions reaffirmed: response to a November 2001 commentary
    Diane Solomon
    Division of Cancer Prevention, National Cancer Institute, Maryland, USA
    Obstet Gynecol 99:671-4. 2002
  4. ncbi request reprint Update on cervical screening
    Diane Solomon
    National Cancer Institute, Division of Cancer Prevention, National Institute of Health, 6130 Executive Blvd, EPN 2130, Rockville, MD 20852, USA
    Gynecol Oncol 99:S13. 2005
  5. ncbi request reprint Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study
    M E Sherman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 7080, Rockville, MD 20852-7374, USA
    Am J Clin Pathol 116:386-94. 2001
    ..ASCUS-H is an uncommon interpretation that derives clinical usefulness from its high positive predictive value for lesions CIN 2 or worse...
  6. pmc Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 203:814-22. 2011
    ..Detailed descriptions of long-term persistence of human papillomavirus (HPV) in the absence of cervical precancer are lacking...
  7. ncbi request reprint Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities
    Diane Solomon
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Obstet Gynecol 110:288-95. 2007
    ....
  8. ncbi request reprint 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ
    Thomas C Wright
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY, USA
    J Low Genit Tract Dis 11:223-39. 2007
    ..To provide updated consensus guidelines for the management of women with cervical intraepithelial neoplasia (CIN) or adenocarcinoma in situ (AIS)...
  9. ncbi request reprint 2006 consensus guidelines for the management of women with abnormal cervical screening tests
    Thomas C Wright
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY, USA
    J Low Genit Tract Dis 11:201-22. 2007
    ..To provide revised evidence-based consensus guidelines for managing women with abnormal cervical cancer screening test results...
  10. pmc Risk assessment to guide the prevention of cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    Am J Obstet Gynecol 197:356.e1-6. 2007
    ....
  11. ncbi request reprint Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852, USA
    Obstet Gynecol 109:1325-31. 2007
    ....
  12. ncbi request reprint 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests
    Thomas C Wright
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
    Am J Obstet Gynecol 197:346-55. 2007
    ..The 2004 Interim Guidance for HPV testing as an adjunct to cervical cytology for screening in women 30 years of age and older was formally adopted with only very minor modifications...
  13. ncbi request reprint 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ
    Thomas C Wright
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
    Am J Obstet Gynecol 197:340-5. 2007
    ..Moreover, management recommendations for women with biopsy-confirmed adenocarcinoma in situ are now included...
  14. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
    ..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...
  15. ncbi request reprint Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial
    Allan Hildesheim
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    JAMA 298:743-53. 2007
    ..Viruslike particle human papillomavirus (HPV) vaccines were designed to prevent HPV infection and development of cervical precancers and cancer. Women with oncogenic HPV infections might consider vaccination as therapy...
  16. ncbi request reprint CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples
    Joseph D Carreon
    Division of Cancer Epidemiology and Genetics, The National Cancer Institute, National Institutes of Health, Department of Health and Human Services Rockville, Maryland 20852, USA
    Int J Gynecol Pathol 26:441-6. 2007
    ..The CIN3 is a substantially more reproducible diagnosis that can be validated more frequently with HPV tests and cytological interpretations than CIN2...
  17. pmc Cervical cancer prevention--cervical screening: science in evolution
    Mahboobeh Safaeian
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, 6120 Executive Blvd, Rockville, MD 20852, USA
    Obstet Gynecol Clin North Am 34:739-60, ix. 2007
    ..This article describes the traditional methods of screening for cervical cancer and innovative methods that might help overcome financial and cultural barriers to more widespread screening...
  18. ncbi request reprint Risk assessment to guide the prevention of cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    J Low Genit Tract Dis 12:1-7. 2008
    ....
  19. doi request reprint Human papillomavirus infection and the primary and secondary prevention of cervical cancer
    Douglas R Lowy
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 113:1980-93. 2008
    ..The manner in which vaccination and screening programs are integrated will need to be considered carefully so that they are efficient in reducing the overall incidence of cervical cancer...
  20. pmc Factors influencing histologic confirmation of high-grade squamous intraepithelial lesion cytology
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 112:637-45. 2008
    ..To examine the predictors of histologic confirmation of high-grade squamous intraepithelial lesion (HSIL) cytology occurring in follow-up of young women originally referred into a trial because of less severe cytology...
  21. pmc Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica
    Rolando Herrero
    Proyecto Epidemiologico Guanacaste, Fundacion INCIENSA, Torre La Sabana, 300 Oeste del ICE, Piso 7, Sabana Norte, San Jose, Costa Rica
    Vaccine 26:4795-808. 2008
    ..4% agreement for all types, kappa 0.59). Follow up will continue with yearly or more frequent examinations for at least 4 years for each participant...
  22. pmc Human papillomavirus genotype specificity of hybrid capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5030, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 46:2595-604. 2008
    ..In conclusion, hc2 cross-reacts with certain untargeted, noncarcinogenic HPV genotypes that are phylogenetically related to the targeted genotypes, but the degree of cross-reactivity may be less than previously reported...
  23. pmc Impact of 6-month frozen storage of cervical specimens in alkaline buffer conditions on human papillomavirus genotyping
    Brandon J LaMere
    Regional Laboratory, Kaiser Permanente Northern California, Berkley, CA, USA
    J Virol Methods 151:298-300. 2008
    ..Six-month frozen storage of cervical specimens at alkaline pH had little impact on testing for HPV genotypes among hc2-positive women using this HPV genotyping method...
  24. ncbi request reprint Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation?
    Mary T Galgano
    Robert E Fechner Laboratory of Surgical Pathology, University of Virginia Health System, Charlottesville, VA 22908 0214, USA
    Am J Clin Pathol 130:65-70. 2008
    ..Thus the HPV-16 fraction was not found to be broadly useful as a quality assurance metric for biopsy diagnosis in this analysis...
  25. pmc Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5004, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 46:109-17. 2008
    ..In conclusion, we found LA to be a promising assay for the detection of HPV genotypes and carcinogenic HPV, and it may be clinically useful for the detection of cervical precancer and cancer in women with equivocal cytology...
  26. pmc A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study
    Patti E Gravitt
    Department of Epidemiology and Molecular Microbiology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 17:1248-54. 2008
    ..We were interested in comparing the performance of Linear Array (LA; Roche Molecular Systems) to Hybrid Capture 2 (hc2; Digene) for the detection of carcinogenic human papillomavirus (HPV) and cervical precancer...
  27. doi request reprint Epidemiology of genital Chlamydia trachomatis infection among young women in Costa Rica
    Carolina Porras
    Proyecto Epidemiologico Guanacaste, Fundacion INCIENSA, San Jose, Costa Rica
    Sex Transm Dis 35:461-8. 2008
    ..To investigate Chlamydia trachomatis (Ct) epidemiology among 5829 women 18 to 25 years old, in Costa Rica...
  28. doi request reprint An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS)
    Philip E Castle
    Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 111:847-56. 2008
    ....
  29. pmc Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections
    Ana Cecilia Rodriguez
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS, Rm 5032, Rockville, MD 20852, USA
    J Natl Cancer Inst 100:513-7. 2008
    ..These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages...
  30. ncbi request reprint The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7234, USA
    Am J Clin Pathol 127:805-15. 2007
    ....
  31. ncbi request reprint Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892 7234, USA
    J Natl Cancer Inst 97:1066-71. 2005
    ....
  32. ncbi request reprint Stability of archived liquid-based cervical cytologic specimens
    Philip E Castle
    The National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, Maryland 20892 7234, USA
    Cancer 99:89-96. 2003
    ..However, long-term DNA stability and cytologic stability of these biospecimens have not been evaluated...
  33. ncbi request reprint Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS)
    Rosemary E Zuna
    Pathology Department, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Cancer 105:253-62. 2005
    ..Using the Atypical Squamous Cells of Undetermined Significance/LSIL Triage Study (ALTS) population, the authors evaluated the significance of HPV-negative LSIL...
  34. ncbi request reprint The carcinogenicity of human papillomavirus types reflects viral evolution
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MA, USA
    Virology 337:76-84. 2005
    ..These results present several clear clues and research directions in our ongoing efforts to understand HPV carcinogenesis...
  35. ncbi request reprint Does the interval between papanicolaou tests influence the quality of cytology?
    Jose Jeronimo
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20892, USA
    Cancer 105:133-8. 2005
    ..It is commonly believed that the sensitivity of Papanicolaou (Pap) tests decreases with a short interval between cytology samplings. To the authors' knowledge, there is only limited evidence to support this belief...
  36. ncbi request reprint A study of the impact of adding HPV types to cervical cancer screening and triage tests
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    J Natl Cancer Inst 97:147-50. 2005
    ..The minimal increases in sensitivity and in negative predictive value achieved by adding HPV types to DNA tests must be weighed against the projected burden to thousands of women falsely labeled as being at high risk of cervical cancer...
  37. ncbi request reprint Interlaboratory reliability of Hybrid Capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Am J Clin Pathol 122:238-45. 2004
    ..73); among those with equivocal or abnormal cytologic findings, kappa values were 0.80 or more. These data show that HC2 is a reliable test for detecting clinically relevant oncogenic HPV DNA...
  38. ncbi request reprint Have we resolved how to triage equivocal cervical cytology?
    Diane Solomon
    J Natl Cancer Inst 96:250-1. 2004
  39. ncbi request reprint Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening
    Thomas C Wright
    Department of Pathology, College of Physicians and Surgeons of Columbia University, Room 16 404 P and S Building, 630 West 168th Street, New York, NY 10032, USA
    Obstet Gynecol 103:304-9. 2004
    ..If test results of either are abnormal, colposcopy should then be performed. This guidance should assist clinicians in utilizing HPV DNA testing in an effective manner, while minimizing unnecessary evaluations and treatments...
  40. ncbi request reprint Findings to date from the ASCUS-LSIL Triage Study (ALTS)
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
    Arch Pathol Lab Med 127:946-9. 2003
    ..Many additional analyses are underway...
  41. ncbi request reprint Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy
    J Thomas Cox
    University of California, Santa Barbara, USA
    Am J Obstet Gynecol 188:1406-12. 2003
    ....
  42. ncbi request reprint American Cancer Society guideline for the early detection of cervical neoplasia and cancer
    Debbie Saslow
    Breast and Gynecologic Cancer, American Cancer Society, Atlanta, GA, USA
    CA Cancer J Clin 52:342-62. 2002
    ....
  43. ncbi request reprint A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    Am J Clin Pathol 124:722-32. 2005
    ..Smaller amounts of material used in PCR could have limited its sensitivity, but our results demonstrate the importance of optimization and standardization of PCR-based assays for clinical applications...
  44. ncbi request reprint The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays
    Mark H Stoler
    Robert E Fechner Laboratory of Surgical Pathology, University of Virginia Health System, Charlottesville, USA
    Am J Clin Pathol 127:335-7. 2007
  45. ncbi request reprint The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life
    Ana Cecilia Rodriguez
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Rockville, Maryland 20859, USA
    Sex Transm Dis 34:494-502. 2007
    ..We wanted to explore early HPV natural history and CIN 3 prospectively...
  46. ncbi request reprint The Bethesda Interobserver Reproducibility Study (BIRST): a web-based assessment of the Bethesda 2001 System for classifying cervical cytology
    Mark E Sherman
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852 7374, USA
    Cancer 111:15-25. 2007
    ..The Bethesda System (TBS) along with its companion atlas was updated in 2001 to improve standardization, clarity, and reproducibility of cervical cytology reporting...
  47. ncbi request reprint Comparison of human papillomavirus distribution in cytologic subgroups of low-grade squamous intraepithelial lesion
    Rosemary E Zuna
    Pathology Department, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    Cancer 108:288-97. 2006
    ..In this study, the objective was to determine whether these 2 morphologic subcategories are characterized by differences in risk for CIN3 and/or HPV type distribution...
  48. ncbi request reprint Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS)
    Joan L Walker
    Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK, USA
    Am J Obstet Gynecol 195:341-8. 2006
    ..Using data from the ASCUS-LSIL Triage Study (ALTS) to inform clinical management, we calculated the absolute risk for developing CIN3 within 2 years of referral to an enrollment colposcopy...
  49. ncbi request reprint Number of cervical biopsies and sensitivity of colposcopy
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 108:264-72. 2006
    ..To examine the influence that type of medical training and number of biopsies have on sensitivity of colposcopically guided biopsies...
  50. ncbi request reprint Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease
    Aimee R Kreimer
    National Cancer Institute, NIH, 6130 Executive Boulevard, Bethesda, MD 20892 7333, USA
    Cancer Epidemiol Biomarkers Prev 15:908-14. 2006
    ....
  51. ncbi request reprint Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes
    Mark E Sherman
    Division of Cancer Epidemiology and Genetics, Hormonal and Reproductive Epidemiology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Cancer 108:298-305. 2006
    ....
  52. ncbi request reprint Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS)
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
    J Natl Cancer Inst 98:92-100. 2006
    ..We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations...
  53. ncbi request reprint Evaluating the risk of cervical precancer with a combination of cytologic, virologic, and visual methods
    Sophia S Wang
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute NIH, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 14:2665-8. 2005
    ..We conclude that the clear discrimination of cervical cancer risk provided by multiple test modalities is consistent with our understanding of cervical etiology related to HPV natural history...
  54. ncbi request reprint Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study
    Richard Guido
    Magee Womens Hospital of the University of Pittsburgh Health Care System, PA, USA
    Am J Obstet Gynecol 188:1401-5. 2003
    ....
  55. ncbi request reprint Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines
    Diane Solomon
    Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
    CA Cancer J Clin 57:105-11. 2007
    ..Potentially, with more appropriate allocation of resources according to guidelines, all women could be screened and the total number of Pap tests reduced, despite projected increases in the population...
  56. ncbi request reprint The distribution of neoplasia arising on the cervix: results from the ALTS trial
    Richard S Guido
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Magee Womens Hospital, Pittsburgh, PA, USA
    Am J Obstet Gynecol 193:1331-7. 2005
    ..This study was undertaken to evaluate the topographic distribution of precancerous intraepithelial lesions on the cervix...
  57. ncbi request reprint Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick Inc, NCI Frederick, Building 469, Room 120, Frederick, MD 21702, USA
    Vaccine 26:3608-16. 2008
    ....